Understanding the cellular mechanisms of tumour growth is key for designing rational anticancer treatment. Here we used genetic lineage tracing to quantify cell behaviour during neoplastic transformation in a model of oesophageal carcinogenesis. We found that cell behaviour was convergent across premalignant tumours, which contained a single proliferating cell population. The rate of cell division was not significantly different in the lesions and the surrounding epithelium. However, dividing tumour cells had a uniform, small bias in cell fate so that, on average, slightly more dividing than non-dividing daughter cells were generated at each round of cell division. In invasive cancers induced by Kras G12D expression, dividing cell fate became more strongly biased towards producing dividing over non-dividing cells in a subset of clones. These observations argue that agents that restore the balance of cell fate may prove effective in checking tumour growth, whereas those targeting cycling cells may show little selectivity.
Understanding the cellular mechanisms of tumour growth is key for designing rational anticancer treatment. Here we used genetic lineage tracing to quantify cell behaviour during neoplastic transformation in a model of oesophageal carcinogenesis. We found that cell behaviour was convergent across premalignant tumours, which contained a single proliferating cell population. The rate of cell division was not significantly different in the lesions and the surrounding epithelium. However, dividing tumour cells had a uniform, small bias in cell fate so that, on average, slightly more dividing than non-dividing daughter cells were generated at each round of cell division. In invasive cancers induced by Kras G12D expression, dividing cell fate became more strongly biased towards producing dividing over non-dividing cells in a subset of clones. These observations argue that agents that restore the balance of cell fate may prove effective in checking tumour growth, whereas those targeting cycling cells may show little selectivity.
Epithelial tumours form when the cellular homeostasis of normal tissue is locally disrupted so that cell production exceeds cell loss (Fig. 1a) . This may result from the rate of tumour cell division being faster than that of normal cells. A second possibility is that in tumours such as squamous cell carcinomas (SCCs) that consist of a mixture of dividing and non-dividing cells, the proliferating tumour cells produce a higher proportion of dividing than non-dividing daughters 1 . This bias in cell fate results in a progressive expansion in the proliferating cell population. Thirdly, the rate of cell loss may be decreased within the tumour relative to the rate of cell production. Here we set out to resolve which of these mechanisms contribute to squamous tumour growth in the oesophagus.
Further insights into the pathogenesis of oesophageal SCC, currently the sixth commonest cause of cancer death worldwide, are urgently needed as even with the most aggressive treatment the majority of patients will die from their disease 2, 3 . Oesophageal SCC is strongly associated with tobacco exposure, and may be preceded by the development of non-invasive lesions called high-grade squamous dysplasias 4, 5 (HGDs). Oesophageal carcinogenesis has been successfully recapitulated in rodents, either by exposing animals to the mutagenic DNA alkylating agent diethylnitrosamine (DEN), which is found in tobacco smoke, or by replicating some of the genomic alterations found in human SCC in transgenic mice [6] [7] [8] [9] [10] [11] [12] . Despite the availability of mouse models, quantifying the behaviour of proliferating cells within intact tumours remains challenging.
One potential approach is lineage tracing, in which expression of a heritable genetic label is induced in individual proliferating cells 13, 14 ( Supplementary Fig. 1a-c) . As the progeny of the labelled cell proliferate and differentiate, they generate clusters of labelled cells, termed clones, as they derive from a single cell. Analysis and statistical modelling of the number of cells in cohorts of simultaneously labelled clones sampled over a prolonged time course has revealed normal cell behaviour and how it is altered by specific oncogenic driver mutations in several tissues, including the oesophageal epithelium 15, 16 . However, the application of this approach to tumours has hitherto been frustrated by extensive inter-and intra-tumoral heterogeneity, which renders the inference of cell behaviour infeasible 14 . Resolving tumour cell behaviour requires a protocol that generates highly similar lesions at a defined time point. Murine oesophageal epithelium is an ideal tissue in which to address this challenge. The normal tissue consists of layers of keratinocytes with proliferation confined to the basal layer 13 . Lineage tracing has shown that the oesophageal epithelium contains only one type of proliferating cell, termed a progenitor. The outcome of individual progenitor divisions is unpredictable, generating either two progenitors or two nondividing, differentiating cells or one cell of each type (Fig. 1b) . In homeostasis, the probabilities of each division outcome are balanced so that equal numbers of progenitors and non-dividing cells are generated across the progenitor population. Wounding, however, drives the progenitors local to the injury to transiently produce an Figure 1 Cell dynamics in oesophageal squamous carcinogenesis. (a) Normal oesophageal epithelium is maintained by a single population of progenitor cells that divide to generate dividing (pink) and post-mitotic cells (white), which exit the basal layer. In homeostatic epithelium, cell production (blue arrow) balances cell loss (red arrow) as proliferating cells generate equal proportions of dividing and non-dividing cells on average. In tumours, an excess of cells is generated locally through one or more of: faster cell division, indicated by the clock, an imbalance in cell fate with a bias towards producing proliferating over non-dividing progeny, ∆, or a decrease in the rate of cell loss relative to the rate of cell production. (b) The outcome of individual progenitor divisions is unpredictable, generating two dividing progenitors or two non-dividing, differentiating cells in symmetric divisions or one cell of each type with the probabilities shown; r is the probability of a symmetric division outcome. In homeostasis, on average equal proportions of dividing and non-dividing cells are generated. During wound healing, local progenitor cells transiently generate an excess of dividing cells until the epithelium is repaired. The probability of generating two dividing cells is increased by ∆, a measure of cell fate bias towards producing proliferating over non-dividing progeny. (c,d) Proliferation in sorafenib-treated oesophageal epithelium. (c) Protocol. Animals were given sorafenib or vehicle alone (control) for 10 days and injected with EdU (purple arrow) 1 h before being euthanized. (d) Confocal z stacks showing 'top down' views of typical epithelial whole mounts, representative of three animals per group; stained for Ki67 (green), EdU (magenta) and 4 ,6-diamidino-2-phenylindole (DAPI, blue). Scale bar, 50 µm. (e-g) Effect of sorafenib on ERK phosphorylation. (e) Protocol. (f) Representative confocal images of epithelial cryosections stained for P-ERK (Thr202/Tyr204, green), basal marker ITGA6 (white) and DAPI (blue). Scale bar, 50 µm. Arrows indicate cells positive for P-ERK. The image is representative of sections from three animals per group. (g) Mean percentage of basal cells staining positive for P-ERK, ( * P = 0.026 by t-test, n = 3 animals per group). See Supplementary Table 4 for source data for g. excess of proliferating daughters until the epithelium is repaired 13, 17 . Mutations inactivating the Notch pathway also bias fate towards proliferation, suggesting the plasticity in progenitor cell behaviour that enables wound healing is a potential vulnerability during neoplastic transformation 15, 18 . Chemical carcinogens such as DEN induce oesophageal tumours but the number of lesions and the time they take to develop varies widely between animals 6 . We drew on the widely used and well-characterized two-stage carcinogenesis protocol in the skin, speculating that following mutagen treatment with a tumour promoting agent might drive the formation of a cohort of tumours sharing a similar phenotype 19 . We noted that side effects of the multikinase inhibitor sorafenib include induction of SCCs of the skin and head and neck in patients treated for liver, kidney and thyroid cancers [20] [21] [22] . This motivated us to test whether sorafenib could promote oesophageal tumour formation in DEN-treated mice.
Here we report that the combination of DEN followed by sorafenib was effective at inducing cohorts of tumours that are sufficiently similar to permit the quantification of cell dynamics using transgenic cell proliferation and lineage tracing assays. We resolved cell behaviour in promoter-treated epithelium, HGD and SCC. The data argue that tumours contain a single proliferating cell population whose behaviour is only subtly perturbed from that of normal progenitors. The line indicates the mean. * * P = 0.003 by two-tailed t-test, n = 12 mice per group. * * * P = 0.0001 by Mann-Whitney test, n = 28 lesions for DEN+S and n = 15 lesions for DEN+V group. (f) Differentiation within lesions. Confocal image of a cryosection from a lesion stained for a terminal differentiation marker, the cornified envelope precursor protein LOR (green), KRT4 (magenta) and basal cell marker KRT14 (white). Scale bars, 200 µm.
(g) Expression of the keratinocyte stress-induced protein KRT6. Confocal image of a cryosection stained for KRT6 (green) and the basal cell marker ITGA6 (white). Scale bars, 200 µm. Images in f,g are typical examples of three lesions. (h-k) Stromal changes beneath HGD lesions. (h) Bright-field image of submucosa paired with the whole mount shown in b. Arrowheads indicate lesions. Scale bar, 1 mm. The image is representative of eight whole mounts. (i) Projected confocal z stack of stroma underlying typical lesion (marked with arrows) stained for capillary endothelial marker CD31 (green), lymphatic endothelial vessel marker LYVE-1 (magenta) and KRT14 (white); scale bar, 200 µm. (j,k) Immune infiltrate in stromal whole mount stained for the myeloid marker CD11b (green) and KRT14 (magenta) (j) and the lymphoid marker CD3 (green) and KRT14 (magenta) (k). Scale bars, 100 µm. Each image is representative of at least three tumours. See Supplementary Table 4 for source data for d,e.
of treatment with sorafenib alone. Ten days of dosing induced a marked dose-dependent increase in proliferation marker expression (Fig. 1c,d and Supplementary Fig. 2a-c) . Treatment for 28 days at a 50 mg kg −1 dose resulted in decreased phosphorylation of ERK and AKT (Fig. 1e-g and Supplementary Fig. 2d-f) . However, tissue integrity was preserved and no tumours developed ( Supplementary  Fig. 2g and Supplementary Table 1) , even when the duration of treatment was extended to 56 days. Apoptosis was negligible ( Supplementary Fig. 2h ). Hence, sorafenib on its own increased proliferation but was not tumorigenic.
Next we studied the combination of sorafenib and the mutagen DEN. Mice were administered sorafenib or vehicle control for 28 days after 56 days of exposure to DEN (Fig. 2a) . The combination of DEN and sorafenib generated an average of three macroscopic tumours per animal with histological features of HGD (loss of normal differentiation, nuclear atypia and loss of cell polarity extending through the entire thickness of the epithelium) (Fig. 2b-e and Supplementary  Table 1) 4 . In contrast, animals treated with DEN and vehicle developed small areas of focal hyperplastic epithelium at a frequency of less than one lesion per mouse (Fig. 2d ,e and Supplementary Table 1) .
We next characterized the DEN/sorafenib-induced HGDs further. Consistent with the disruption of terminal differentiation seen histologically, we observed a loss of expression of the cornified envelope precursor proteins LOR and FLG in lesions by immunostaining ( Fig. 2f and Supplementary Fig. 3a) . Expression of KRT14, confined to the basal layer in normal epithelium, was widespread, and KRT4, normally detected in the first suprabasal layer was seen only in and above the third and fourth suprabasal cell layers (Fig. 2f) . We also observed increased expression of the keratinocyte stress-induced proteins KRT6, induced in squamous tumours in humans and mice, and KRT17, a regulator of tumour-associated transcription ( Fig. 2g and Supplementary Fig. 3b ) [23] [24] [25] . We detected apoptosis in only 0.08 ± 0.05% (mean ± s.e.m.) of cells ( Supplementary Fig. 2h ).
The dysplastic cells did not breach the basement membrane but protruded into the underlying submucosa (Fig. 2h) . Threedimensional (3D) confocal imaging revealed substantial stromal remodelling beneath the lesions. There was marked angiogenesis and lymphangiogenesis with a leukocytic infiltrate including CD11b-and CD3-positive cells closely associated with the deep margin of HGDs, features also seen in murine and human squamous dysplasia and SCC (Fig. 2i-k and Supplementary Fig. 3c ) [26] [27] [28] [29] [30] . We concluded that sorafenib promotes tumour formation in DEN-treated epithelium.
We next investigated whether the common histological phenotype of the lesions was reflected at a transcriptional level. Whereas the transcriptomes of HGDs and normal adjacent epithelium differed markedly, there was comparatively little variation between HGDs (Fig. 3a) . Gene ontology categories that were significantly different between normal epithelium and HGDs included keratinocyte differentiation-and inflammation-associated transcripts, consistent with our findings above (Supplementary Tables 2 and 3) . Transcripts of genes involved in RNA splicing, a process dysregulated in epidermal carcinogenesis, were also differentially expressed 31 (Fig. 3b) . We validated the relative expression of selected messenger RNAs in epithelium and HGDs by quantitative PCR with reverse transcription, observing marked upregulation of cytoskeletal-associated transcripts (Fig. 3c ).
Clonal origin of HGD lesions
Malignant transformation is thought to be a process in which lesions originate from the progeny of a single cell that progressively acquires multiple oncogenic genomic alterations 32, 33 . However, dysplastic lesions in several mouse and human tissues have been shown to be polyclonal [34] [35] [36] [37] [38] [39] . We therefore investigated the clonal origin of the HGD lesions by genetic lineage tracing. We induced a heritable genetic marking with the confetti allele, which labels cells with one of four different fluorescent proteins ( Supplementary Fig. 1a,b . Animals were then treated with DEN and sorafenib and epithelial whole mounts of HGD lesions imaged (Fig. 3d) . If lesions arose from the clonal progeny of a single cell, they would be either unlabelled or completely labelled with a single colour. If, however, HGDs derived from multiple cells, variegated labelling with multiple different coloured clones would be seen. We observed a mean of 2.7 clones (range 1-6) in 9 labelled lesions, which ranged widely in size (n = 5 animals) (Fig. 3e-g ). Similar results were obtained when the experiment was repeated with a single-colour labelling system in Ahcre ERT Rosa26 flYFP/wt mice, in which cells are labelled with a yellow fluorescent protein (YFP) reporter (Supplementary Figs 1c  and 3d-g ) 13 . We conclude that HGDs have multiple cells of origin.
Kras
G12D expression in combination with DEN/sorafenib treatment results in invasive squamous cell carcinomas
We speculated that altering the protocol might generate invasive SCCs rather than HGDs. We noted that mutations, amplifications or overexpression of growth factor receptor tyrosine kinases and genes in their downstream signalling pathways, including KRAS, are present in the majority of human oesophageal SCCs [42] [43] [44] . Furthermore, oncogenic KRAS mutations are frequent in cutaneous SCCs in patients treated with sorafenib 45 . These observations led us to investigate the effects of inducing the oncogenic Kras G12D mutant in oesophageal epithelium after DEN exposure and before treatment with sorafenib ( Supplementary Fig. 1d ) 46 . This protocol resulted in lethal, invasive SCCs in 11/14 animals ( Fig. 4a-d and Supplementary Table 1) . We observed increased phospho-Erk levels in the carcinomas, consistent with Kras activation in the lesions (Fig. 4e) . Consistent with our findings in dysplasias, KRT14 stained positive throughout the tumours, while expression of the terminal differentiation marker LOR was abrogated ( Supplementary Fig. 4a,b) . The carcinomas shared a similar transcriptome (Fig. 4f) . Among the differences in transcription between HGD and SCC were significant induction of the inflammation-associated mRNAs Ifngr2 and Fcer1g and changes consistent with Kras activation in SCCs (Fig. 4g,h and Supplementary Fig. 4c ). A limitation of inducing SCCs with this protocol is that we were unable to use lineage tracing to determine whether the tumours were monoclonal or polyclonal in origin.
Proliferating cell dynamics in sorafenib-treated epithelium
The data above show that the combination of DEN and sorafenib was effective in inducing HGDs and SCCs that shared similar features. We therefore set out to quantify how proliferating cell behaviour changed in promoter-treated epithelium, HGD and SCC.
We began by analysing the effect of sorafenib treatment by using the dilution of a transiently expressed transgenic histonegreen fluorescent protein (HGFP) to infer the mean rate of epithelial cell division 13, 47, 48 . Transgenic animals were treated with doxycycline (Dox) to induce HGFP transcription from a synthetic Dox-regulated promoter, resulting in high-level expression of HGFP throughout the epithelium 49,50 ( Supplementary Fig. 1e ). Following withdrawal of Dox, HGFP levels were measured by confocal imaging of epithelial whole mounts. Histone mRNA is short-lived, so HGFP message is unlikely to persist following Dox withdrawal and the cessation of transcription 51, 52 . Assuming that the rate of HGFP protein degradation is small compared with the cell cycle time, the rate of HGFP decrease will reflect the rate at which it is diluted by cell division (Fig. 5a-c Relative units * * * * * * * * 
Relative units
Relative units * * * * * * * * * * * * * * * * * * * * * * * Values are means of independent biological replicates (n = 8 biological replicates for Myd88, n = 6 for Krt6b, Krt17, Ccnd2, Ctnnb1, Raf1, Pten, n = 5 for Fcerg1, Ifngr2, and n = 4 for Sprr2f, Igfbp2 in both g and h), normalized to the control (=1). Error bars are s.e.m. * P < 0.05 * * P < 0.01; * * * P < 0.001 by Mann-Whitney test. NS, not significant. See Supplementary Table 4 for source data and exact P values for d,g,h.
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cell division rate rose from once every 3.5 days in controls to a rate of once a day during sorafenib treatment ( Supplementary Fig. 5a ,b and Supplementary Note 2.1).
To address how the fate of individual progenitor cells was perturbed by treatment with sorafenib, we used lineage tracing, inducing sparse genetic labelling with YFP to yield well-separated clones in Ahcre ERT Rosa26 flYFP/wt mice during a course of sorafenib treatment 13 (Fig. 5d ). Twelve days after clonal induction, animals were euthanized, and multicellular YFP-expressing clones (233 from 3 animals) were imaged ( Fig. 5d-f and Supplementary Fig. 5c -f Table 4 for source data for c,f, and Supplementary Table 5 for fitting error margins in g.
and Supplementary Table 4 ). To assess whether the clone size data could be accommodated within the cell fate paradigm of normal oeosphageal epithelium (Fig. 5g) , we implemented cell fate rules in a stochastic model, which was simulated for a wide range of parameters (Supplementary Note 1.2.2). Taking the cell cycle times determined by HGFP dilution as a prior, we found the best match of model and data using Bayesian inference (Fig. 5f ). This confirmed that the data comply with the same paradigm as normal epithelium, but with a marked increase in both the proportion of divisions leading to asymmetric fate and the rate of cell stratification, in line with the increased cell division rate (Fig. 5f ,g and Supplementary Table 4 for source data for h,i.
Cell dynamics in dysplasia
Next we investigated proliferating cell behaviour within HGD lesions. To map the location of proliferating cells, animals were injected with EdU ( Fig. 6a) 
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. After 24 h, the vast majority of EdU + cells were found at the edge of lesions (Fig. 6b) . However, 5 days later, residual EdU + cells were found in the centre of the lesion, arguing that non-dividing cells migrate from the proliferative rim to the core of the lesion where they accumulate (Fig. 6c ). This was confirmed by HGFP dilution assay, which showed that cells retaining detectable levels of HGFP remained in the centre of the lesions for at least 38 days after Dox withdrawal, but were absent elsewhere in the tissue (Fig. 6d,e) . We concluded that HGDs were characterized by a centripetal migration of cells from the proliferative margin to the non-dividing centre, a phenomenon also reported in human squamous tumours 1 . A possible explanation for the retention of non-dividing cells is that the disrupted expression of proteins required for late terminal differentiation reduces the rate of shedding of dysplastic cells from the surface of the lesion in comparison with normally differentiated cells in the adjacent epithelium ( Fig. 2f and Supplementary Fig. 3a ).
Next we estimated the rate of cell division in HGD and the adjacent epithelium ( Table 4 for source data for c,g,h.
division rate was once per day both in the lesion and the surrounding epithelium, assuming the stability of HGFP is not altered by neoplastic transformation ( Table 4 ). The clone size distribution remained unimodal, consistent with dividing cells belonging to a single progenitor population following a defined stochastic fate. We therefore sought the simplest modification of normal cell dynamics that could accommodate the observed clone sizes, in the form of a constant statistical bias in cell fate towards the production of proliferating cells. We thus simulated the original model relaxing the previous restriction on equal cell fate ratios, and tested this model on the clone size distributions through Bayesian inference ( Fig. 1b and Supplementary Note 2.3). This showed an excellent agreement between experiment and theory and gave a bias of around 4% towards divisions producing two cycling over two non-dividing cells (Fig. 7c,d and Supplementary  Table 5 and Supplementary Note 2.3). The rate of cell loss was also reduced (Fig. 7d and Supplementary Table 5 and Supplementary Note 2.3). This is consistent with both the observed disruption of the differentiation process that occurs before cell shedding from the epithelial surface and the accumulation of non-dividing cells in the lesion core ( Fig. 2f and Supplementary Figs 3a and 6c,e) . Analysis of the clone size distribution in the surrounding epithelium indicated that the cell dynamics were not significantly different from those of epithelium in mice treated with sorafenib alone, suggesting that the effects of the combination of DEN and sorafenib treatment on cell behaviour are confined to the HGD lesions ( Supplementary Fig. 6g ). To further validate the analysis, we repeated the experiment in mice carrying the confetti reporter allele, which allows labelling with four different colours, thereby reducing the probability that clones with the same colour merge to create a misleadingly large apparent 'clone' (Fig. 7e-g and Supplementary Note 2.3). We obtained similar results to YFP for all parameters but the loss rate, which was increased in the confetti experiment. This discrepancy may be attributed to the higher sensitivity of detection of labelled cells in the singlecolour assay, in which immunostaining was used to visualize YFP expression (see Methods). We concluded that a single proliferating cell population with a small constant cell fate bias towards the production of dividing cells is responsible for the growth of the dysplastic lesions (Fig. 7d) .
This analysis made the counterintuitive prediction that the proportion of dividing cells amongst the total cell population should be decreased within HGD compared with the surrounding epithelium, as the decreased rate of cell loss in HGD would result in the accumulation of non-dividing cells. The proportion of cells expressing the proliferation-associated antigen Ki67 was indeed reduced within HGD (Fig. 7h) . Table 4 ). The YFP allele was less efficiently recombined than the Kras G12D allele, resulting in sparse labelling in tumours. In these experiments, the clones reflect the fate of labelled cells and their progeny from when they were labelled in normal-appearing epithelium at the end of DEN treatment until they are sampled within SCCs. We observed that 26/31 SCCs contained an average of 5 (range 1-20) YFP-positive clones (Fig. 8e) . Two-thirds of the clones had a size distribution quantitatively consistent with the cell dynamics seen in HGD (Fig. 8b ,f,g and Supplementary Fig. 7c and Supplementary Note 2.4). The sizes of the vast majority of the remaining clones could be captured within the same model paradigm, but with a larger bias towards proliferating cell fate (Fig. 8c,h and Supplementary  Fig. 7d and Supplementary Note 2.4). Only 2% of clones expanded significantly faster than the model prediction (Fig. 8d,f) , suggesting that the same paradigm of progenitor dynamics applies to almost all clones in SCCs, but with a variable bias in cell fate (Fig. 8i) . Strikingly, as with HGDs, the proportion of Ki67-positive cells was lower in SCCs than in the surrounding normal epithelium (Fig. 8j and Supplementary Fig. 7e ).
Cell dynamics in squamous cell carcinoma

Conclusion
In summary, the DEN/sorafenib carcinogenesis protocol generates multiple, synchronous and phenotypically similar oesophageal HGDs. Additional expression of an oncogenic Ras allele generates invasive SCCs. These tumours are sufficiently similar to allow the quantitative resolution of cell dynamics and offer a model of carcinogenesis that can be combined with transgenic tools to explore many other aspects of tumour biology.
Linage tracing reveals that cells in dysplasias share a common dynamics despite their polyclonal origin. It remains to be resolved whether a single clone recruits surrounding cells or whether multiple clones collaborate in establishing a lesion.
Within oesophageal tumours, we show that dividing cells are a single population with a bias towards the production of dividing over non-dividing daughter cells and no significant change in the rate of cell division (Supplementary Fig. 7f ). In dysplasia, cell behaviour is remarkably uniform with a small constant fate bias. In contrast, early carcinoma is characterized by the emergence of a subset of clones with an increased bias towards proliferation that compete for dominance within the tumour 33,54 . Our results also argue that the 'cancer stem cell' hypothesis, which proposes that tumour expansion depends on a hierarchy of proliferating cells, does not apply to squamous neoplasia in mice 55, 56 . We conclude that targeting imbalanced cell fate may provide an attractive strategy to arrest tumour progression.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper. (Figs 3a and 4f) for which only male animals were used. Mice were 3-8 months of age at the start of experiments.
The cell division rate was quantified using R26 M2rtTA /TetO-HGFP mice carrying a reverse tetracycline-controlled transactivator (rtTA-M2) targeted to the Rosa26 locus and a HIST1H2BJ/EGFP fusion protein (HGFP) expressed from a tetracycline responsive promoter element 49, 50 . Doxycycline treatment in these animals results in nuclear labelling of basal cells in the oesophageal epithelium with HGFP. After withdrawal of doxycycline, HGFP transcription ceases and the protein is diluted by cell division. To label cells, R26
M2rtTA /TetO-HGFP mice were treated with doxycycline (Sigma) at 2 mg ml −1 in sweetened drinking water for 4 weeks. To visualize clones, whole mounts from Ahcre ERT R26 flEYFP/wt animals were immunostained with an anti-GFP antibody before imaging, while whole mounts from Ahcre ERT R26 flConfetti/wt animals were imaged unstained. Ahcre ERT R26 flEYFP/wt LSL Kras +/G12D mice were induced by i.p. injection of a single dose of 20 mg kg −1 β-naphthoflavone and 0.25 mg tamoxifen. To visualize clones, samples were immunostained with an anti-GFP antibody before imaging.
Chemical carcinogenesis. To induce tumour formation, animals were treated with DEN (Sigma) in sweetened drinking water (40 mg per 1,000 ml) 3 times a week for 8 weeks 6 . Sorafenib (LC Chemicals) was administered by i.p. injection as a solution at 10 mg ml −1 dissolved in cottonseed oil containing 5% dimethylsulfoxide. Control animals received a vehicle control (5% dimethylsulfoxide in cottonseed oil).
To investigate the effect of sorafenib, a dose response evaluation was carried out, based on published xenograft studies 59 . Injections (i.p.) of sorafenib were given on alternate days for 10 days and the proportion of basal cells expressing the proliferation markers EdU and Ki67 in a total number of n = 10 fields of view from two different animals at each dose level was determined by confocal imaging of epithelial whole mounts. Based on these results, a dose of 50 mg kg −1 i.p. on alternate days was chosen for further experiments.
Immunostaining. Oesophageal whole mounts were prepared by cutting the oesophagus into 4 or 5 pieces of approximately 5 mm in length, which were incubated in 5 mM EDTA for 2-3 h at 37 • C. The oesophageal epithelium was peeled away from the underlying tissue and was fixed in 4% paraformaldehyde (PFA) at room temperature for 15-30 min. For staining, whole mounts were blocked in staining buffer (0.5% bovine serum albumin, 0.25% fish skin gelatin and 0.5% Triton X-100 in PBS) with 10% of serum from the species the secondary antibodies were raised in for 1 h at room temperature. Whole mounts were then stained with primary antibodies in staining buffer overnight at 4 • C and with fluorochrome-conjugated secondary antibodies for 3 h at room temperature or overnight at 4 • C. Following antibody incubation, whole mounts were washed four times with 0.2% Tween-20 in PBS for 2 h in total. Whole mounts were incubated with DAPI (1 µg ml −1 ) in PBS overnight at 4 • C and were finally mounted using Vectashield Mounting Medium with DAPI (Vector Labs).
Primary antibodies used for immunostaining are listed in Supplementary  Table 7 .
Oesophageal cryosections of 10 µm thickness were fixed with 4% PFA for 5-10 min. Sections were blocked and permeabilized with blocking buffer (0.3% Triton X-100 and 10% serum of the species the secondary antibody was raised in diluted in PBS) for 1 h at room temperature. Sections were incubated with primary antibodies overnight at 4 • C in antibody dilution buffer (1% BSA and 0.3% Triton X-100 in PBS) and with the fluorochrome-conjugated secondary antibody in antibody dilution buffer for 1 h at room temperature. Sections were washed with PBS following antibody incubations.
For the analysis of invasive tumours in Ahcre ERT R26 flEYFP/wt LSL Kras +/G12D mice, tissue was fixed in 4% PFA for 30-60 min. The tissue was embedded in low-melting agarose and sections of 100-120 µm thickness were cut using a Vibratome (Leica).
Sections were subsequently permeabilized for 1 h and stained as described above for whole mounts.
EdU incorporation was detected using a Click-iT EdU Imaging kit (Life Technologies) according to the manufacturer's instructions. If detection of EdU was combined with immunofluorescent staining, EdU detection was performed between primary and secondary antibody incubation.
All immunofluorescence images are representative of at least three animals.
Microscopy.
Images were acquired on a Zeiss LSM 510 META, a Leica TCS SP5 II or a Leica TCS SP8 (Leica Microsystems) confocal microscope using ×10, ×20, ×40 or ×63 objectives. Typical settings for acquisition of z stacks were optimal pinhole, line average 3-4, scan speed 400 Hz and a resolution of 1,024 × 1,024 pixels or 2,048 × 2,048 pixels. Image analysis was performed using Volocity 3D Image Analysis Software (Perkin Elmer).
Histone 2B-EGFP (HGFP) dilution rate. HGFP dilution was quantified as described. After withdrawal of doxycycline, HGFP was allowed to dilute and the oesophageal epithelium of R26 M2rtTA /TetO-HGFP animals was analysed at 0 h, that is, immediately after 4 weeks of labelling, and at 24 h, 48 h and 72 h. Animals remained untreated for the remaining days. Whole mounts were imaged unstained on a Leica TCS SP5 II confocal microscope using identical settings for all samples. Single 2-µm-thick optical sections of the basal layer were taken and the fluorescence intensity of individual nuclei was measured using Volocity Improvision software (Perkin Elmer). For quantification, at least 3 animals were analysed per time point and fluorescence intensity of at least 100 nuclei per animal was measured. Following sorafenib treatment 3 animals were analysed per time point (4 at 72 h). In dysplastic lesions, 4 animals were analysed at 48 h, 6 animals at 72 h; in adjacent epithelium, 3 animals per time point.
Validation of model predictions following sorafenib treatment. Firstly, we measured the stratification rate by labelling cycling cells administering a pulse of 5-ethynyl-2-deoxyuridine (EdU) to mice treated with sorafenib for 28 days. EdU is taken up by cells in S phase and then partitioned between daughter cells following division. We analysed the location of the labelled cells, quantifying the proportion of EdU-positive cells in the basal and suprabasal layers, 24 h post EdU injection, and checked whether this was consistent with the estimate of the stratification rate from lineage tracing. We also measured the orientation of mitoses by 3D confocal imaging. The model predicts a high proportion of asymmetric divisions and rapid average stratification rate of differentiating cells. This may in part be achieved by altering the orientation of mitosis relative to the basement membrane from parallel to the basement membrane towards perpendicular.
Spindle orientation.
To analyse spindle orientation, oesophageal whole mounts were stained for pericentrin and mitoses were z-stacked using DAPI nuclear stain with a 63× objective, zoom 3 (ref. 60). The xyz-coordinates of pericentrin staining were then recorded in Volocity software and the division angle relative to the basal plane was calculated as described. At least 30 mitoses from 2 different animals were measured.
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Bioconductor was used 62 . Gene ontology analysis was performed using GOstats (2.32.0) 63 . The normalized expression values were used for hierarchical clustering using complete linkage. For any other statistical and visualized methods R (version 3.1.3) was used. To find potential protein-protein interactions String database (version 10) was used with default settings 64 . Exported data were visualized using Cytoscape (version 3. 3) 64 . Complementary cDNA synthesis of 200 ng of total RNA was performed using the QuantiTect reverse transcription kit (Qiagen). The cDNA synthesis reactions without reverse transcriptase yielded no amplicons in PCR reactions. Quantitative PCR with reverse transcription was performed with specific primers (Supplementary Table 6 ) and QuantiTect SYBR Green PCR master mix (Qiagen) according to the manufacturer's instructions using a StepOnePlus Real Time PCR system (Applied Biosystems).
Relative quantitation was performed and each mRNA was normalized to Hprt mRNA as an internal control. The relative levels of each mRNA were expressed as ratios to the control values set to unity. To test significance, Mann-Whitney tests were performed comparing CT values.
Statistics and reproducibility.
The analysis of the lineage tracing and H2GFP dilution experiments is described in the Supplementary Note. Source data and exact P values for statistical tests are listed in Supplementary Table 4 .
Experimental data are presented as mean ± standard error of the mean (s.e.m.), unless otherwise stated. Statistical analysis was performed using the Graphpad Prism software. The D' Agostino-Pearson omnibus test was used to test for normality and the F-test was used to test for a significant difference in variance between groups. Student's unpaired t-test was performed for normally distributed data where there was no significant difference in variance between groups. For non-normally distributed data, Mann-Whitney or Kolmogorov-Smirnov tests were performed.
To Table 4 for source data for a-f, h-j, m, p and q. In histologically normal epithelium, even after exposure to nitrosamine and Sorafenib, cell production (green arrow) equals cell loss (red arrow). Proliferating cell fate is balanced, generating equal proportions of dividing and non-dividing cells on average. In tumours, an excess of dividing cells is generated locally. This is achieved through a small bias in cell fate towards producing proliferating progeny, Δ, and a reduction in the rate of cell loss relative to cell production.
Supplementary Note
In this supplementary note we outline the mathematical analysis of the data and the modelling scheme for cell fate dynamics in oesophageal epithelium treated with diethylnitrosamine (DEN) and Sorafenib. The models are challenged on data from cell lineage tracing experiments. In those experiments, clones are scored by their cell numbers (clone size) and from the statistical ensemble of clones, we determine the frequency distribution of clone sizes, the clone size distribution (CSD). These data serve as the basis to test the validity of the models and to determine model parameters through fitting.
First, the established model for homeostatic cell fate dynamics in oesophagus (1) is introduced and challenged on clonal data from Sorafenib-treated tissue. For modelling the cell fate dynamics in high-grade squamous dysplasia (HGD) and invasive tumours, we suggest a simple adjustment of this model to account for cell fate imbalance and test whether this is consistent with cell lineage data.
Modelling and Fitting procedure
Basic model: From clonal analysis of oesophagus (1) it is known that progenitor cell fate evolves according to the paradigm of stochastic cell fate (2, 3). In this model, oesophageal progenitors P divide stochastically with rate λ and either daughter cell may exit cell cycle and commit to differentiation, termed a D-cell, according to the rules
The probabilities of gain and loss of progenitor cells, given by the fate outcomes P → P + P and P → D + D must be equal to achieve homeostasis. Following division, D-cells may migrate to the suprabasal layers (stratification, with rate γ), then denoted as D * -cells.
Finally, cells progress toward terminal differentiation, and eventually lose their nuclei (with rate σ), after which they are considered lost
This model has been shown to describe clonal dynamics in normal oesophagus (1). Here we test if these cell fate rules also hold for tissue challenged by the treatment of Sorafenib. For that purpose, the quantitative predictions for clonal evolution are compared with the experimentally obtained clone size distributions (CSDs). We employ stochastic simulations, using a Gillespie algorithm (4), to compute the time evolution of clones. In these simulations, the stochastic Bayesian certainty (also called Bayesian posterior probability)
where P (D|θ) =: L(θ) is the likelihood of θ, i.e. the probability that the model with parameter values θ reproduces the data, and the prior P (θ) is the a priori certainty of the model parameters, without taking into account D. The factor N = θ P (D|θ)P (θ) is a normalisation for the probability. The prior P (θ) is an estimate of the parameter certainty due to information from other sources, e.g. previous measurements. We choose as a prior the distribution with maximal entropy, matching the given information. Without further information this is a uniform distribution; if a mean and variance is known, and the variance is much smaller than the mean 2 , we choose a normal distribution as prior.
In our case, we have additional information on cell kinetics by measurements of Histone-GFP (HGFP) dilution (see section 2.1) which restricts the possible range for the cell division rate. In these measurements the cell division rate is determined with meanλ and standard error σ λ by linear regression. The maximum entropy prior for given mean and standard error is a normal distribution
The , and the Bayesian certainty P (θ|D) is determined for each θ (see Ref. (5) for details). For each set of parameters, n = 150000 clones are simulated and the Bayesian certainty is determined according to Eq. 6, and the prior, Eq. 5. The benchmarks of the parameter space scan are given in Table 1 . The parameter values θ * with the maximum Bayesian certainty, P * := P (θ * |D), are chosen as best fit parameter values.
In order to determine error margins for parameters, we compute the root-mean-squared deviation of parameters from θ * when distributed according to the Bayesian posterior probability distribution that has been determined as described above. For that purpose, n=10000
parameter value points θ α (α = 1, ..., n) are generated randomly, following the Bayesian posterior probability distribution. The error of each parameter θ i is then computed as
Error margins of data points in clone size distributions: Since the abundance of clones of a given clone size may be very small in the experimental data, it is subject to substantial statistical noise. In order to obtain the range of deviations from the expected clone frequencies, we simulate by our model the data fluctuations due to small clone sample numbers. In that process, we run the stochastic simulations n = 1000 times repeatedly, taking the best fit parameters θ * and simulate the same total clone number as counted in the lineage tracing experiments. Each sample simulation j gives a prediction for the clone frequencies f We have also checked the mouse-to-mouse variations in the clone counts and found that they are comparable to the error originating from small sample size error.
Data analysis and model fitting results
In this section we analyse the HGFP fluorescence data to obtain estimates for the cell division rate, and we fit cell fate models to clonal data from oesophageal epithelium that has been disturbed by various measures (administration of Sorafenib and DEN). The best fit parameter values and parameter error margins will be determined according to the procedure described in the last section (rates in units of 1/w = per week, or 1/d = per day).
Cell division rate from analysis of the HGFP dilution data
In can therefore distort the average, which is meant to be over progenitor cells only. Therefore we need to correct for non-dividing cells, as will be outlined in the following.
Denoting by n i the mean number of progenitor cells and m i the mean number of nondividing cells in generation i, respectively, the time evolution of the cell populations in each generation reads
where λ is the cell division rate, and γ the stratification rate of non-dividing cells. It is assumed that progenitor cells are not immediately lost, and that cell fate imbalance does not play a 
where ρ := N/Z is the fraction of progenitor cells. The meansī P,D have the time evolution
With the substitution i
so that
Withī P,D (t = t 0 ) = 0, and since in the stationary state N/M = γ/λ, we get the solution of these ordinary differential equations
Differentiating for t and substitution of this result in Eq. 8 gives
Hence, the slope of the time course of the mean cell generation of all cells is a good approximation for the cell division rate λ of progenitor cells for large times t γ, or if λ ≈ γ.
Since the result depends only on the time derivative of the mean cell generation -which does not depend on f 0 -we can define the reference fluorescence level f 0 as the fluorescence at 24
hours, thus counting cell generations from day 1 after Dox withdrawal. Thereby uncertainties in the time scale of Dox withdrawal are avoided.
The mean cell generation, defined asī(t) = log 2 (f 0 /f (t)) , is shown as a function of time in Supplementary Fig. 5a for Sorafenib-only treated tissue and in We see in Supplementary Fig. 5a and Fig. 6i that the data points follow a straight line with constant slope for each case. This suggests, according to Eq. 13, that we are in the regime where the slope of i(t) approximates the cell division rate well. With this approximation, a linear regression yields in all three cases a cell division rate very close to once per day. The results of the fitting and error margins (standard deviation of the fit's χ 2 -distribution) are shown in Supplementary Fig. 6d , as well as the corresponding residuals which estimate the s.e.m.
of the individual data points. In the following we will use this information for constructing a
Bayesian prior for fitting the clonal data. As a maximum entropy prior with given mean and variance, we use a Gaussian function P (λ) = (2πσ
) whereλ is the best fit value of the regression and σ λ its standard error (see Supplementary Fig. 6d ).
The distributions of cell generation times are shown in Supplementary Figs . 5b,6b,c for Sorafenib-only treatment, DEN+Sorafenib treatment inside HGD, and DEN+Sorafenib treatment in tissue adjacent to HGD, respectively. Remarkably, for Sorafenib-only treatment, the generation distributions keep their shape and are merely shifted by one cell cycle between subsequent days which indicates that cell cycle times are highly uniform with a length of 24 hours.
This would be expected if cell divisions were limited by the circadian clock and is consistent with the strong diurnal regulation of proliferation in the oesophagus (6).
Clonal analysis in Sorafenib-treated tissue
In the first experiment, animals were pre-treated with Sorafenib for 28 days before clones were induced, and tissue was harvested 12 days later. In order to infer cell fate dynamics in tissue treated with Sorafenib, we fit the parameters of the model according to the procedure outlined in section 1. The benchmarks of the fitting procedure (scanning the parameter space for determining the Bayesian certainty distribution) are given in Table 1 . The resulting best fit parameter values and root-mean-square errors are given by λ = 7.0 ± 0.2/w r = 0.02 ± 0.01 γ = 6.8 ± 0.9/w σ = 2.6 ± 0.2/w ,
The error margins denote root-mean-square deviations from the best fit values as described in section 1. clones with a single basal cell are excluded 3 . This is shown in Supplementary Fig. 5e , where the basal CSD from the experiment and model predictions for parameters of normal oesophageal epithelium, taken from Ref. (1), are compared.
Comparing the best fit parameters for tissue from Sorafenib-treated mice with normal tissue (see Supplementary Table 5) , we see that the ratio of symmetric cell divisions r is significantly decreased, so that almost all cell divisions (1 − 2 r = 96%) result in asymmetric fate outcome.
Furthermore, both the stratification rate and the cell division rate are significantly increased.
Clonal analysis in tissue treated with Sorafenib and DEN
For studying cell fate dynamics in HGD, mice were treated with DEN for 8 weeks, and then Sorafenib was administered for 4 weeks before clones were induced. 13 days and 22 days after induction the mice were culled and clones counted. 
The corresponding detailed CSD is shown, together with the data, in Supplementary Fig. 6g , which shows an excellent agreement. As expected, we see that these best fit parameter values are not very different from the case of Sorafenib-only treatment; there is an overlap of the acceptable parameter regimes, except for a slightly significant difference in the symmetric division ratio r. Thus, DEN treatment does not markedly alter cell fate dynamics in non-dysplastic tissue.
Clonal analysis in HGD:
Inside HGDs we expect cell fate dynamics to be non-homeostatic.
In this case, we sought for the minimal adjustment of the homeostatic model that could capture the clonal dynamics, by assuming normal cell fate dynamics of the form given by rules 1, but with a tilt towards proliferation:
where δ quantifies the tilt in cell fate 4 (δ = 0 corresponds to homeostasis δ = 1 implies absence of symmetric cell cycle exit). Furthermore, we accommodate the observation that proliferating cells are also found in the suprabasal layers of the dysplastic epithelium and that non-dividing cells show signs of early differentiation, but terminal differentiation is suppressed. Therefore, we do not explicitly distinguish between basal and suprabasal cells in the model, and we only consider one type of non-dividing cell D, irrespective of the distance to the basement membrane and differentiation stage. Non-dividing D-cells are shed with loss rate µ:
Note that loss of D-cells may thus occur before terminal differentiation. In order to compare this with the loss of cells in normal stratified epithelium, we need to find a corresponding quantity in latter case. We note that µ = 1/τ , where τ is the mean "life time" of a D-cell, from birth to loss. For scenarios in which basal and suprabasal cells are distinguished, the mean life time is τ = 1/γ + 1/σ. Thus, in this case, the absolute loss rate is µ = (1/γ + 1/σ) −1 and the values for the different scenarios can be compared, as given in Supplementary Table 5 .
To fit the model, we compared the distributions of total clone sizes (total CSD) between model and experiment, according to Eq. 4, at both 13 and 22 days post-induction (multiplying likelihoods at both time points). The benchmarks of scanning the parameter space to find bestfit values and error margins are shown in Table 1 . The resulting best fit parameter values and root-mean-square errors are given by: λ = 7.0 ± 0.1/w r = 0.05 ± 0.02 µ = 0.9 ± 0.7/w δ = 0.4 ± 0.2 .
With these parameter values, the corresponding plot of the clone size distribution (model prediction and data) is shown in Fig. 7c for clonal data 13 days after induction and in Supple- The simulation results with the best fit parameters match well both the clonal data at 13 days and at 22 days post-induction, apart from a few outliers with very large clone size. However, it cannot be excluded that clones merge, forming polyclonal clusters that cannot be distinguished, due to identical colours. We therefore repeated the experiment with mice carrying a confetti allele, which allows randomly labelling with four different colours, thereby reducing the probability that clones with the same colour merge. Fitting this clonal data gives the best fit parameters λ = 6.95 ± 0.05/w r = 0.03 ± 0.015 µ = 2.0 ± 0.3/w δ = 0.7 ± 0.3 .
where the error ranges denote the standard deviation of the Bayesian posterior. In this fit a single outlier with clone size 59 cells was excluded from the data at 21 days after induction. Fig. 7g and Supplementary Fig. 6h shows the corresponding clone size distributions 10 and 21 days after clonal induction, showing good agreement between model and data. The parameters from fitting both the single colour and the confetti assay are similar with overlapping error ranges in the parameters λ, r, and δ. However, the loss rate µ is significantly higher for the confetti mouse data, which may be explained by the higher sensitivity for differentiated cells in the single colour assay.
Furthermore we check theoretically whether the outliers in the single-colour data are within the range of expected clone fusion events. (1 − φ) s P (s,s)
where P (s,s) is the probability distribution of clone widths (mean clone widths), which, ac-cording to our assumption above, corresponds to the distribution of progenitor cell numbers in a clone. According to our model, the progenitor cells perform a supercritical branching process which follows the distribution P (s,s) = e −s/s × (e 1/s − 1) (7). With a cell division rate of λ = 7.0/w and a loss rate of µ = 0.9/w (best fit values) we have an equilibrium fraction of proliferative cells of ρ = µ/(µ + λ) = 11.4% in a clone. 13 days after induction, the mean size of clones is n 13 = 9.57, yieldings = ρ n 13 = 1.09. From Eq. 21 we then getP t = 0.961, corresponding to an expected fraction of merged clones of P t = 1 −P t = 3.9%. We see 5 clones out of 100 counted (5%) to lie outside the error margin of the model prediction for the data taken 13 days after induction and 4 out of 68 (5.9%) after 22 days. This is is well consistent with the 
Kras-induction and Sorafenib administration after treatment with DEN
In the final experiment, an oncogenic Kras mutant was induced together with YFP after 8 weeks of DEN administration. When clones were induced, also Sorafenib treatment started. Invasive tumours emerged, and at 42 and 56 days after induction clones were scored in those tumours.
The number of clones that could be recorded is scarce and the computational effort required for effective model fitting is too high to perform because of the large clone sizes. Yet we can check whether the cell fate paradigm of pre-malignant lesions in oesophagus prevails. To assess this, we first checked whether some clones follow the same dynamics as clones in pre-malignant DEN-induced HGD, despite of Kras activation. For that purpose we first restrict our analysis to "small" clones by defining a cut-off size up to which clones are considered. The cut-off is chosen as the average maximal clone size one would expect under the clonal dynamics observed in HGDs, and can be determined by extreme value theory (8) . Assuming an exponential CSD, the expected maximum clone size is z max = (ln(N ) + γ e ) ×z, where N is the number of clones, γ e the Euler-Mascheroni constant, andz the mean clone size. This results in an expected maximum clone size of 147 at 42 days after induction and a maximum expected maximum size of 147 at 56 days after induction. We will thus use these numbers as cut-off for our analysis.
Considering only clones below this threshold (65 out of 98 at 42 days, and 25 out of 40 at 56 days after induction), the clonal data is matched well by the prediction from model 17 with the parameters inferred for HGD clonal dynamics, without Kras, as shown in Fig. 8g at 42 days after induction and in Supplementary Fig. 7c at 56 days after induction. Hence, for the majority of clones, Kras induction does not have a significant impact on clonal dynamics.
However, there is still a large fraction of clones which are significantly larger than would be expected from dynamics in pre-malignant HGD. We want to test if these clones can yet be described by the tilted stochastic fate paradigm, rules 17, albeit with a higher cell fate bias. Although we cannot fit the data, we can use an analytical approximation for the model prediction:
after long times the clone size distribution approaches a distribution as expected from a supercritical branching process, which yields an exponential distribution P (z) = 1/z exp(−z/z), wherez is the mean clone size (7) . Thus, the model rules 17 would predict the data points to From this data are excluded the 'mega-clones' with several thousands of cells which do not match the predicted distributions. Although it could be possible that an even higher cell fate bias can accommodate for their size, the number of those clones is too small to test this.
